Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034840 · ClinicalTrials.gov registry record · Phase 4
Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
A Phase 4 study of Hypertension, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 490
- Enrollment target
- 20
- Study locations
NCT00034840: Completed Phase 4 study of Hypertension, sponsored by Boehringer Ingelheim.
NCT00034840 is a Phase 4 study of Hypertension that has completed, run by Boehringer Ingelheim. The registered enrollment target is 490 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00034840, a Phase 4 study of Hypertension, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 490 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
Conditions Studied
Interventions
- DRUG telmisartan, valsartan
Study Locations (20)
California
- Memorial Research Medical Clinic - Long Beach
- National Research Institute - Los Angeles
- Orange County Research Center - Orange
Florida
- Alan Graff - Fort Lauderdale
- Greater Ft. Lauderdale Heart Group Research - Fort Lauderdale
- Orlando Clinical Research Center - Orlando
Nova Scotia
- Dr. William Booth - Antigonish Nova Scotia
- MSHJ Research Assoc. - Halifax
Connecticut
- University of Conn. Health Services Center, Hypertension and Vascular Disease - Farmington
Georgia
- So. Clinical Research and Management, Inc. - Augusta
Illinois
- Rush Presbyterian/St. Luke's Medical Center - Chicago
Maryland
- University of Maryland/Nephrology Clinical Research Unit - Baltimore
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2001-10 |
| Est. Completion | 2002-08 |
| Phase | Phase 4 |
What the finished NCT00034840 record still lists
NCT00034840 is an interventional study that assigns participants to a tested intervention. The registered 490 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which telmisartan, valsartan is the first listed.
NCT00034840 names 20 study sites across 15 states, led by California, Florida, Nova Scotia.
Frequently Asked Questions
What is clinical trial NCT00034840 about?
NCT00034840 is a clinical study titled "Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose". The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDI...
What is the current status of trial NCT00034840?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 490 participants. The study started on 2001-10. Estimated completion is 2002-08.
What conditions does trial NCT00034840 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00034840?
The interventions under investigation include: telmisartan, valsartan (DRUG).
Who is sponsoring clinical trial NCT00034840?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00034840 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00034840's enrollment target sits among peer trials
490 124th of 470 higher than 347 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04728893 · 490 participants · Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- NCT06238479 · 490 participants · Phase 1
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- NCT06336928 · 490 participants
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
- NCT06641414 · 490 participants · Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia